利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.01 秒)

    TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH CAMPATH-1H
    1.
    发明公开
    TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH CAMPATH-1H 审中-公开
    百慕达馄饨（SK）MIT CAMPATH-1H

    公开(公告)号：EP3028718A1

    公开(公告)日：2016-06-08

    申请号：EP15191491.8

    申请日：2007-09-11

    申请人： Alcafleu Management GmbH & Co. KG ,  Genzyme Corporation

    发明人： SACHSE, Andreas ,  MARGOLIN, David Harris

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/2893 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24

    摘要： A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ≤ 12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1 - 24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.

    摘要翻译： 描述了用Campath-1H治疗多发性硬化（MS）的方法，其具有显着的功效和良好的安全性，其提供了可接受的益处/风险比。 特别描述了Campath-1H（alemtuzumab）用于生产治疗多发性硬化症（MS）的药物的用途，其包括第一个治疗周期，随后是至少一个Campath-1H（alemtuzumab）的治疗周期， 每个治疗周期包括连续施用的1-5个日剂量，其中日剂量> 0和‰¤12mg，并且其中每个治疗周期与下一个周期分开至少1-2个月。 还描述了包括施用少于12mg /天的Campath-1H连续1-5天的治疗方案。

    TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH CAMPATH-1H
    3.
    发明公开
    TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH CAMPATH-1H 有权
    多发性硬化与CAMPATH-1H处理（MS）

    公开(公告)号：EP2066352A1

    公开(公告)日：2009-06-10

    申请号：EP07802348.8

    申请日：2007-09-11

    申请人： Bayer Schering Pharma Aktiengesellschaft ,  Genzyme Corporation

    发明人： SACHSE, Andreas ,  MARGOLIN, David Harris

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/2893 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24

    摘要： A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ≤ 12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1 - 24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.